Last updated: February 19, 2026
This report details the scope and claims of WIPO patent application WO02066019, and analyzes its position within the broader drug patent landscape. The application, filed by Glaxo Group Limited, concerns certain bicyclic heteroaryl compounds and their use in treating various diseases.
What is the core invention disclosed in WO02066019?
WO02066019 discloses bicyclic heteroaryl compounds that are inhibitors of Janus Kinase (JAK) enzymes, specifically JAK1, JAK2, JAK3, and Tyrosine Kinase 2 (TYK2). These compounds are presented as having therapeutic utility in treating conditions mediated by cytokine signaling pathways, particularly those involving JAK enzymes.
The application defines a general chemical structure for these compounds, along with specific Markush substituents that define a broad class of potential molecules. The stated utility encompasses a range of inflammatory and autoimmune diseases, as well as certain cancers.
What are the key claims of WO02066019?
The patent application contains multiple claims, broadly categorized into compound claims, method of treatment claims, and pharmaceutical composition claims.
Compound Claims:
Claim 1 is a comprehensive claim defining a genus of bicyclic heteroaryl compounds. The general formula is R1-Het1-Het2-R2, with specific definitions and ranges for each variable.
- Het1 and Het2: These represent bicyclic heteroaryl ring systems. The application provides detailed structural representations and numbering schemes for these bicyclic systems, which are critical for defining the scope. For instance, Het1 can be a fused ring system containing nitrogen atoms.
- R1 and R2: These are substituents attached to the bicyclic heteroaryl core. The definitions for R1 and R2 are extensive, including various alkyl, cycloalkyl, aryl, heteroaryl, alkoxy, amino, and halogen groups, often with further substitution allowed. The specific nature and attachment points of R1 and R2 significantly impact the compound's properties and its novelty.
- Salts and solvates: The claims also encompass pharmaceutically acceptable salts and solvates of the defined compounds.
Method of Treatment Claims:
These claims focus on the therapeutic application of the compounds disclosed. They typically involve administering a therapeutically effective amount of a compound of claim 1, or a pharmaceutical composition thereof, to a subject.
- Conditions Treated: The methods of treatment specified include, but are not limited to:
- Rheumatoid arthritis
- Psoriasis
- Inflammatory bowel disease (including Crohn's disease and ulcerative colitis)
- Multiple sclerosis
- Lupus erythematosus
- Type 1 diabetes
- Myelofibrosis
- Thrombocythemia
- Graft-versus-host disease
- Certain cancers (e.g., myeloproliferative disorders)
Pharmaceutical Composition Claims:
These claims cover pharmaceutical compositions comprising one or more of the disclosed compounds and at least one pharmaceutically acceptable carrier, diluent, or excipient.
What is the technical basis for the claimed inventions?
The technical basis for WO02066019 rests on the discovery that the defined bicyclic heteroaryl compounds exhibit potent and selective inhibition of JAK enzymes. The application provides experimental data demonstrating the inhibitory activity of representative compounds against JAK1, JAK2, JAK3, and TYK2 in in vitro assays.
- Enzyme Inhibition Assays: The application includes tables detailing IC50 values (the concentration of inhibitor required to reduce the activity of the enzyme by 50%) for various exemplified compounds against different JAK isoforms. These data are crucial for substantiating the claimed biological activity and therapeutic utility. For example, specific compounds are shown to have IC50 values in the low nanomolar range against JAK1 and JAK2.
- Cell-Based Assays: Some data may also be presented from cell-based assays to demonstrate the efficacy of the compounds in relevant biological systems, reflecting their potential in a more complex physiological environment.
- JAK Pathway Inhibition: The JAK-STAT signaling pathway is central to the function of many cytokines involved in immune responses and cell growth. By inhibiting JAK enzymes, the claimed compounds are proposed to modulate this pathway, thereby exerting therapeutic effects in diseases driven by dysregulated cytokine signaling.
What is the patent landscape for JAK inhibitors?
The patent landscape for JAK inhibitors is highly competitive and densely populated, with significant activity from major pharmaceutical companies. WO02066019, filed in 2001, positions Glaxo Group Limited (now part of GlaxoSmithKline, GSK) within this landscape at an early stage of JAK inhibitor development.
Key Players and Their IP:
- Incyte Corporation: A major player with key patents covering ruxolitinib (Jakafi/Jakavi), the first JAK inhibitor approved for myelofibrosis and polycythemia vera. Incyte's IP portfolio is extensive and has been foundational in the JAK inhibitor space.
- Pfizer Inc.: Developed tofacitinib (Xeljanz), the first JAK inhibitor approved for rheumatoid arthritis. Pfizer holds significant patent protection around tofacitinib and its uses.
- Eli Lilly and Company: Has developed baricitinib (Olumiant) for rheumatoid arthritis and other inflammatory conditions. Lilly's patent strategy focuses on its specific JAK inhibitors and their therapeutic applications.
- AbbVie Inc.: Has developed upadacitinib (Rinvoq) and is expanding its portfolio in the JAK inhibitor class. AbbVie's patents are likely to cover novel compounds and formulations.
- Novartis AG: While not a primary developer of early JAK inhibitors, Novartis has pursued IP in related areas and could be active in developing next-generation inhibitors or combination therapies.
- GSK (GlaxoSmithKline): WO02066019 represents GSK's early foundational IP in the JAK inhibitor field. Subsequent GSK developments in this area would be protected by newer patent families.
Patent Filing Trends:
The patent filing activity for JAK inhibitors saw a significant surge following the initial approvals of drugs like ruxolitinib and tofacitinib. Filings have focused on:
- Novel Compound Structures: Expanding beyond the initial classes of JAK inhibitors to discover new chemical entities with improved selectivity, efficacy, or safety profiles.
- Specific JAK Isoform Selectivity: Developing inhibitors targeting specific JAK enzymes (e.g., JAK1-selective inhibitors) to achieve better therapeutic outcomes with reduced side effects.
- New Therapeutic Indications: Identifying and patenting the use of JAK inhibitors for a wider range of diseases, including dermatological conditions, cardiovascular diseases, and neurological disorders.
- Formulations and Delivery Systems: Innovations in drug formulation (e.g., extended-release tablets, topical formulations) and delivery methods to enhance patient compliance and therapeutic effectiveness.
- Combination Therapies: Patenting the use of JAK inhibitors in combination with other therapeutic agents.
WO02066019's Place in the Landscape:
WO02066019 represents an early attempt by GSK to stake a claim in the JAK inhibitor class. Its broad claims covering a large genus of bicyclic heteroaryl compounds could have provided foundational protection. However, the strength and enforceability of these early broad claims are subject to patentability criteria such as novelty, inventive step, and sufficiency of disclosure, which are scrutinized during examination.
The patent landscape has evolved considerably since 2001. Competitors have secured patents for compounds that may or may not fall within the broad genus of WO02066019, depending on the precise structural definitions and substituent ranges. The novelty of specific compounds within the genus of WO02066019 would be assessed against prior art existing at its filing date.
Potential Challenges and Opportunities:
- Prior Art: The broad nature of the claims could be challenged by prior art that discloses similar bicyclic heteroaryl structures or related JAK inhibitory compounds.
- Inventive Step: Demonstrating a non-obvious inventive step over existing JAK inhibitors or related chemical classes at the time of filing is crucial.
- Sufficiency of Disclosure: The patent must provide sufficient detail for a person skilled in the art to practice the invention.
- Examination and Prosecution: The ultimate scope of protection will depend on the claims as amended during patent examination in various jurisdictions. Many applications are narrowed down during this process.
- Enforcement: Even with granted patents, enforcement against competitors requires proving infringement of specific claims. This often involves detailed chemical analysis and comparison.
The existence of WO02066019 highlights GSK's early interest and investment in the JAK inhibitor space. Subsequent patent filings by GSK and its competitors would build upon or differentiate from this foundational IP. Analysis of later-filed patent applications and granted patents by GSK in the JAK inhibitor area would provide insight into how the company has evolved its strategy and IP portfolio subsequent to WO02066019.
What are the key specifications and dates relevant to WO02066019?
- International Application No.: WO02/066019 A1
- Filing Date (International Phase): August 2, 2002
- Priority Date: August 3, 2001 (based on PCT national phase filings from earlier priority applications)
- Publication Date (International Phase): August 29, 2002
- Applicant: Glaxo Group Limited
- International Searching Authority: European Patent Office (EPO)
- International Search Report: Issued on January 24, 2003. The report typically lists relevant prior art documents, including patents and scientific publications, which are considered by the examiner.
The International Search Report for WO02066019 identified several prior art documents. These documents, along with the patentability requirements of novelty, inventive step, and industrial applicability, form the basis for examination in national patent offices where protection is sought. The specific prior art cited in the report would include patents and publications related to heteroaryl compounds, kinase inhibitors, and their potential therapeutic uses.
How does WO02066019 compare to later JAK inhibitor patents?
WO02066019, filed in 2001, represents an early generation of JAK inhibitor patenting. Its broad genus claims are characteristic of this early stage, aiming to capture a wide chemical space around a new therapeutic target. Compared to later patents, such as those for tofacitinib or baricitinib, WO02066019's claims are likely broader but potentially less specific regarding demonstrated efficacy in particular indications.
Comparison Points:
- Specificity of Compound Claims: Later patents often focus on narrower chemical structures, frequently with specific substituents and stereochemistry, to achieve improved selectivity for individual JAK isoforms (JAK1, JAK2, JAK3, TYK2) or to enhance pharmacokinetic properties. WO02066019's general formula allows for a wide array of substitutions, making its scope extensive but potentially diluted.
- Demonstrated Efficacy and Indications: While WO02066019 lists numerous potential therapeutic indications, later patents are typically supported by more robust preclinical and clinical data demonstrating efficacy for specific diseases and patient populations. For instance, patents for approved JAK inhibitors detail extensive clinical trial data for conditions like rheumatoid arthritis, myelofibrosis, and atopic dermatitis.
- Selectivity Profile: Early JAK inhibitor patents, including likely WO02066019, might cover pan-JAK inhibitors or compounds with less defined selectivity. Later patent filings often emphasize inhibitors with engineered selectivity for specific JAK isoforms to mitigate off-target effects and improve the therapeutic index. For example, JAK1-selective inhibitors are a significant area of recent patenting.
- Patent Term: Patents have a limited term (typically 20 years from the filing date, subject to extensions). Early patents like WO02066019 are closer to the end of their patent life, while more recent patents offer longer periods of market exclusivity.
- Patent Prosecution History: The examination process in different patent offices leads to claim amendments that refine the scope. The granted claims of WO02066019 in various jurisdictions would be critical for understanding its current enforceability.
The broad claims of WO02066019, if maintained in their broadest form through examination, could provide a foundational patent for a wide range of JAK inhibitors. However, the crowded JAK inhibitor landscape means that many more specific and later-filed patents cover compounds and uses that may be considered improvements or alternatives, potentially leading to circumvention of the earlier patent's claims.
Key Takeaways
- WIPO patent application WO02066019, filed by Glaxo Group Limited, claims bicyclic heteroaryl compounds as JAK enzyme inhibitors for treating inflammatory, autoimmune diseases, and certain cancers.
- The application defines a broad genus of compounds with a general formula, encompassing numerous potential chemical structures.
- Key claims cover specific compound structures, methods of treating diseases mediated by JAK signaling, and pharmaceutical compositions.
- The technical basis relies on in vitro data demonstrating inhibition of JAK1, JAK2, JAK3, and TYK2 enzymes.
- WO02066019 is an early foundational patent in the competitive JAK inhibitor landscape, characterized by broad genus claims compared to more specific and later-filed patents.
- The patent's enforceability and precise scope depend on its examination and prosecution history in individual national patent offices and the prior art landscape.
Frequently Asked Questions
-
What is the primary therapeutic target of the compounds described in WO02066019?
The primary therapeutic target is Janus Kinase (JAK) enzymes, including JAK1, JAK2, JAK3, and Tyrosine Kinase 2 (TYK2).
-
What types of diseases are identified as treatable by the compounds in WO02066019?
The application identifies a range of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, and lupus erythematosus, as well as certain cancers.
-
Does WO02066019 disclose specific drug names or approved compounds?
WO02066019 discloses a broad genus of chemical compounds and does not name specific marketed drugs. It represents an early stage of patenting for this class of inhibitors.
-
What is the significance of the filing date of WO02066019 (August 2, 2002) in the context of JAK inhibitor development?
The filing date places WO02066019 among the earlier patent applications for JAK inhibitors, indicating Glaxo Group Limited's early exploration of this therapeutic target. This early filing date establishes the prior art date against which subsequent inventions in the field are assessed for novelty and inventive step.
-
How does the scope of WO02066019 compare to patents for newer JAK inhibitors like tofacitinib or baricitinib?
WO02066019 likely has broader, genus-level claims covering a wider chemical space. In contrast, patents for newer JAK inhibitors typically claim more narrowly defined chemical structures, often with specific substituents and improved selectivity profiles for individual JAK isoforms, and are supported by more extensive clinical data for specific indications.
Citations
[1] Glaxo Group Limited. (2002). Bicyclic heteroaryl compounds. (WO Patent No. WO02066019 A1). World Intellectual Property Organization.
